EVOLUS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
EVOLUS INC. - More news...
EVOLUS INC. - More news...
- Evolus Reports First Quarter 2020 Results and Provides Business Update
- Evolus to Report First Quarter 2020 Financial Results and Provide a Business Update on Monday, May 11, 2020
- Evolus Provides Strategic Business Update
- Evolus Provides Update on International Trade Commission (ITC) Case
- Evolus to Participate in Barclays 2020 Global Healthcare Conference
- Evolus Reports Fourth Quarter and Full Year 2019 Results and Provides Business Update
- Evolus to Participate in 9th Annual SVB Leerink Global Healthcare Conference
- Evolus to Report Fourth Quarter and Full Year 2019 Financial Results and Provide a Business Update on Tuesday, February 25, 2020
- Positive Results from Phase III, Split-Face, Head-to-Head Study Comparing OnabotulinumtoxinA and PrabotulinumtoxinA in the Treatment of Crow’s Feet Lines Published in Dermatologic Surgery
- Evolus Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenue
- Evolus to Participate in Stifel Healthcare Conference
- Evolus Announces Pricing of Public Offering of Common Stock
- Evolus Announces Proposed Public Offering of Common Stock
- Evolus Reports Third Quarter 2019 Financial Results and Provides Business Update
- Evolus to Report Third Quarter 2019 Financial Results and Provide a Business Update on Monday, November 4, 2019
- Evolus and Clarion Medical Technologies Announce First Shipment of Nuceiva™ (prabotulinumtoxinA) to Customers in Canada
- Evolus Receives Approval for Nuceiva™ in the European Union
- Evolus will Participate in Cantor Global Healthcare Conference
- Evolus Announces Successful Completion of the Jeuveau® Experience Treatment (J.E.T) Program
- Evolus to Participate in Two Upcoming Investor Conferences
- Evolus Reports Second Quarter 2019 Financial Results
- Evolus to Report Second Quarter 2019 Financial Results and Provide a Business Update on Monday, August 12, 2019
- Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D.
- Evolus Provides Update on Nuceiva™ Marketing Authorization Application in Europe
- Evolus Accelerates Next Phase of U.S. Launch of Jeuveau™ with ‘#NEWTOX NOW’ Consumer Conversion Program
- Evolus to Participate in Three Upcoming Investor Conferences
- Evolus Announces First Shipment of Jeuveau™ (prabotulinumtoxinA-xvfs) to Customers in the United States
- Evolus Reports First Quarter 2019 Financial Results
- Evolus to Participate in Two Upcoming Investor Conferences
- Evolus Receives Positive CHMP Opinion for Nuceiva™ in the European Union
